Insmed Incorporated (NasdaqGS: INSM)
Health Care · Biotechnology · US
$124.39
+0.40% today · -5.9% 1Y
Insmed Incorporated (NasdaqGS: INSM) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.16B and employs 1,664 people.
Over the last twelve months the share price has lost 5.9%, trading between 90.39 and 212.75.
Tweenvest scores Insmed Incorporated across four factors: quality 26/100, value 73/100, growth 98/100. Its strongest factor is growth.
INSM price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.16B
- Revenue (TTM)
- $1.14B
- P/E
- —
- EPS
- -4.09
- Dividend yield
- —
- Beta (5Y)
- 0.79
- 52-week high
- $212.75
- 52-week low
- $90.39
- Avg volume (3M)
- —
- Shares outstanding
- 218.38M
- Employees
- 1,664
- Next earnings
- —
About Insmed Incorporated
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
- ISIN
- US4576693075
- Founded
- 1988
- Listed since
- Jun 1, 2000
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.